[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 - CAS 213130-17-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C61H102N22O14
Molecular Weight:
1367.6
COA:
Inquire
Targets:
Opioid Receptor
Description:
[Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2 is the first selective antagonist to prevent the binding of the endogenous ligand orphanin FQ​/Nociceptin (OFQ​/N) at the orphan opioid-​like receptor, demonstrated both in vitro and in vivo. It is selective, competitive antagonism at the nociceptin receptor has also been reported (pA2 = 7.02 and 6.75 in the guinea pig ileum and mouse vas deferens respectively).
Sequence:
FGGFTGARKSARK
(Modifications: Phe-1-Gly-2 peptide bond replace with Psi-(CH2-NH), Lys-13 = C-terminal amide)
Synonyms:
(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S,3R)-2-[[(2S)-2-[[2-[[2-[[(2S)-2-amino-3-phenylpropyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]acetyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]propanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]hexanamide; N-[(2S)-2-Amino-3-phenylpropyl]glycylglycyl-L-phenylalanyl-L-threonylglycyl-L-alanyl-L-arginyl-L-lysyl-L-seryl-L-alanyl-L-arginyl-L-lysinamide; N-[(2S)-2-Amino-3-phenylpropyl]-13-L-lysinamide-2-13-orphanin FQ (swine)
Solubility:
Soluble to 0.70 mg/ml in water
Storage:
Store in a cool and dry place (or refer to the Certificate of Analysis).
MSDS:
Inquire
InChIKey:
ZHKMSRDIVOXQKP-YILJZHMHSA-N
InChI:
InChI=1S/C61H102N22O14/c1-35(75-48(87)33-74-59(97)50(37(3)85)83-57(95)45(29-39-18-8-5-9-19-39)77-49(88)32-73-47(86)31-70-30-40(64)28-38-16-6-4-7-17-38)52(90)79-44(23-15-27-72-61(68)69)55(93)81-42(21-11-13-25-63)56(94)82-46(34-84)58(96)76-36(2)53(91)80-43(22-14-26-71-60(66)67)54(92)78-41(51(65)89)20-10-12-24-62/h4-9,16-19,35-37,40-46,50,70,84-85H,10-15,20-34,62-64H2,1-3H3,(H2,65,89)(H,73,86)(H,74,97)(H,75,87)(H,76,96)(H,77,88)(H,78,92)(H,79,90)(H,80,91)(H,81,93)(H,82,94)(H,83,95)(H4,66,67,71)(H4,68,69,72)/t35-,36-,37+,40-,41-,42-,43-,44-,45-,46-,50-/m0/s1
Canonical SMILES:
CC(C(C(=O)NCC(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(C)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNCC(CC2=CC=CC=C2)N)O
1.Spontaneous transient outward currents: modulation by nociceptin in murine dentate gyrus granule cells.
Shirasaki T;Houtani T;Sugimoto T;Matsuda H Brain Res. 2001 Nov 2;917(2):191-205.
Spontaneous transient outward currents have been found in peripheral neurons and smooth muscle cells, but rarely in central neurons. Using a nystatin-perforated patch clamp technique, we succeeded in recording spontaneous transient outward currents in mouse dentate gyrus granule cells. Nociceptin/orphanin FQ increased the amplitude and frequency of transient outward currents. We consider modulation of spontaneous transient outward currents to be a new means to regulate cell activity in central neurons, and studied their characteristics and mechanism of augmentation. The whole-cell current-voltage relationship showed outward rectification and the reversal potential was close to the equilibrium potential for K+. The frequency of spontaneous transient outward currents increased at depolarized potentials. Tetraethylammonium, iberiotoxin and a Ca2+ chelator BAPTA-AM inhibited spontaneous transient outward currents. These results suggest the involvement of large-conductance Ca2+-activated K+ channels. Single-channel recordings in the inside-out configuration revealed Ca2+-activated K+ channels with a conductance ranging from 82 to 352 pS. The augmenting effect of nociceptin/orphanin FQ was cancelled by [Phe1psi(CH2-NH)Gly2]Nociceptin(1-13)NH2.
2.Modulation of the cardiac autonomic transmission of pithed rats by presynaptic opioid OP4 and cannabinoid CB1 receptors.
Malinowska B;Piszcz J;Koneczny B;Hryniewicz A;Schlicker E Naunyn Schmiedebergs Arch Pharmacol. 2001 Sep;364(3):233-41.
We studied the effects of nociceptin, the endogenous ligand of the opioid OP4 receptor, and of two cannabinoid receptor agonists WIN 55,212-2 and CP-55,940 (0.001-1 micromol/kg each) on the neurogenic tachycardia and bradycardia in pithed rats. Electrical stimulation (1 Hz, 1 ms, 50 V for 10 s) of the preganglionic sympathetic nerve fibres and injection of nicotine 2 micromol/kg or isoprenaline 0.5 nmol/kg increased heart rate by about 70 beats/min (bpm) in pithed rats pretreated with atropine 1.5-2 micromol/kg. The electrically induced tachycardia was reduced dose dependently by nociceptin, WIN 55,212-2 and CP-55,940 (by 60, 30 and 20% at the highest dose, respectively). The OP4 and cannabinoid receptor agonists diminished the nicotine- but not the isoprenaline-stimulated increase in heart rate. In pithed rats pretreated with propranolol 3 micromol/kg, vagal stimulation (5 Hz, 1 ms, 15 V for 10 s) or injection of methacholine (5-10 nmol/kg) decreased heart rate by about 30 bpm. Nociceptin, but not WIN 55,212-2 or CP-55,940 decreased the vagal bradycardia dose dependently (the inhibitory effect of 1 micromol/kg was about 40%). Nociceptin failed to modify the methacholine-induced decrease in heart rate.
3.[Phe1psi(CH2-NH)Gly2]nociceptin-(1-13)-NH2 acts as an agonist of the orphanin FQ/nociceptin receptor in vivo.
Grisel JE;Farrier DE;Wilson SG;Mogil JS Eur J Pharmacol. 1998 Sep 11;357(1):R1-3.
The orphanin FQ/nociceptin (OFQ/N) derivative peptide, [Phe1psi(CH2-NH)Gly2] nociceptin-(1-13)-NH2 (Phe(psi)), has been claimed to be both an antagonist and an agonist of the orphan opioid receptor (ORL1) in different in vitro assays. We now report the dose-dependent inhibition of morphine analgesia by Phe(psi) in mice, an effect parallel to that of OFQ/N. Further, the anti-opioid actions of OFQ/N are not blocked by Phe(psi). Thus, Phe(psi) acts as an ORL1 receptor agonist, not an antagonist, in vivo.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Opioid Receptor Products


CAS 103429-31-8 CTOP

CTOP
(CAS: 103429-31-8)

CTOP has been found to be an effective and selective μ opioid receptor antagonist and could be used in the treatment of pain.

CAS 16590-41-3 Naltrexone

Naltrexone
(CAS: 16590-41-3)

Naltrexone, also called as Celupan, competitively antagonise μ, κ, δ, and σ-opioid receptors with the effect to reduce the occurrence of addictive behaviours .

CAS 113158-35-3 Nor-Binaltorphimine dihydrochloride

Nor-Binaltorphimine dihydrochloride
(CAS: 113158-35-3)

Nor-Binaltorphimine dihydrochloride is a potent and selective kappa opioid receptor antagonist.

CAS 126766-32-3 GR 89696 fumarate

GR 89696 fumarate
(CAS: 126766-32-3)

GR 89696 fumarate is a potent and selective κ-opioid agonist (IC50 = 0.04 nM) displaying anti-nociceptive and neuroprotective activity.

CAS 103429-32-9 CTAP

CTAP
(CAS: 103429-32-9)

CTAP has been found to be a selective μ-opioid receptor antagonist.

GSK1521498
(CAS: 1007573-18-3)

GSK-1521498 is a novel μ-Opioid receptor antagonist. It shows to attenuate reward-driven compulsive behaviours, such as stimulant drug seeking or binge eating i...

LY 106737
(CAS: 82970-72-7)

LY 106737 is phenylpiperidine opioid receptor antagonist, but no detailed information has been published yet.

CAS 863513-91-1 Cebranopadol

Cebranopadol
(CAS: 863513-91-1)

Cebranopadol is a novel first-in-class compound with potent agonist activity on opioid receptor like-1(ORL-1) and the well established mu opioid receptor. It sh...

Chemical Structure

CAS 213130-17-7 [Phe1Ψ(CH2-NH)Gly2]Nociceptin(1-13)NH2

Quick Inquiry

Verification code

Featured Items